A+ A A- Skip to main content

Asian Paints

2356.4 -4.30

Cipla

1211.2 -18.30

Eicher Motors

7092.5 -331.50

Nestle India

1227.6 -21.70

Grasim Inds

2723.1 -19.50

Hindalco Inds.

977.35 -14.75

Hind. Unilever

2123 -32.30

ITC

299.35 -4.90

Trent

3879.7 -36.80

Larsen & Toubro

3959.9 0.00

M & M

3233.9 -25.90

Reliance Industries

1313.6 -36.60

Tata Consumer

1091.2 -2.50

Tata Motors PVeh

344.8 2.20

Tata Steel

205.63 -0.98

Wipro

202.7 -2.18

Apollo Hospitals

7528.5 17.00

Dr Reddy's Labs

1229.1 -3.10

Titan Company

4490.5 -14.50

SBI

1055.45 -11.25

Shriram Finance

1006.7 -20.85

Bharat Electron

444.4 1.95

Kotak Mah. Bank

370.45 -4.10

Infosys

1272.3 -20.20

Bajaj Finance

900.95 -23.60

Adani Enterp.

2136 49.20

Sun Pharma.Inds.

1658.5 3.60

JSW Steel

1206.9 -7.90

HDFC Bank

792.75 -17.55

TCS

2477.1 -47.20

ICICI Bank

1336.8 14.90

Power Grid Corpn

301.7 -1.05

Maruti Suzuki

13018 -691.00

Axis Bank

1355 4.20

HCL Technologies

1426 -25.20

O N G C

285.7 -0.80

NTPC

387.7 7.55

Coal India

435.7 1.60

Bharti Airtel

1878.7 8.70

Tech Mahindra

1434.5 -5.70

Jio Financial

237.37 -5.83

Adani Ports

1472.9 -2.40

HDFC Life Insur.

622.55 18.40

SBI Life Insuran

1930.4 7.20

Max Healthcare

960.6 7.25

UltraTech Cem.

11500 -89.00

Bajaj Auto

9793 -20.50

Bajaj Finserv

1783 -26.20

Interglobe Aviat

4449.6 -104.60

Eternal

236.64 -3.59

Corporate News - Detailed News Back
Lupin receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets
08-Apr-26   19:18 Hrs IST
Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg.

The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo' XR for the indications in the approved labeling.


DJIA 47930.49
-276.32 -0.57%
S&P 500 6837.38
-8.28 -0.12%
HANG SENG 25893.55
141.14 0.55%
NIKKEI 225 56484.90
-439.21 -0.77%
FTSE 100 10596.33
-7.15 -0.07%
NIFTY 23825.65
-224.95 -0.94%
×
Ask Your Question
close
refresh